New urine test aims to catch bladder cancer early

NCT ID NCT01563796

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a urine test that measures a protein called DEK to help diagnose bladder cancer. It included over 1,100 people with blood in their urine or painful urination. The goal was to see if the test could accurately detect cancer without invasive procedures. However, the trial was stopped early, so the final results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DEK ELISA urine test
What this could lead to
If successful, this could provide a simple, non-invasive urine test to help diagnose bladder cancer earlier.
What could go wrong
The trial was terminated, so results are incomplete. The test may not be accurate enough to replace standard methods like cystoscopy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dysuria Hematuria urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Staten Island University Hospital

    Staten Island, New York, 10305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.